Delivery Order HHSN261201200033I-HHSN26100011
Award Date 9/15/17
Potential Completion Date 6/30/23
Potential Value $1.4M
Federal Agency
Ultimate Awardee
NAICS Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost No Fee
Place of Performance
Madison, WI 53715, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
3
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The National Cancer Institute issued a delivery order to the University of Wisconsin System on July 1, 2015, with a ceiling value of $261,352 under the Cancer Prevention Agent Development Program 2012-2017. The order funds a randomized, double-blind, Phase I dose-escalation study of the novel retinoid 9CUAB30, a cancer prevention agent under early-phase clinical research. Place of performance is Madison, Wisconsin. The order is priced on a cost, no-fee basis and has an ultimate completion date...
- This federal contract award was made by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to the University of Wisconsin - Madison, operating as Research and Sponsored Programs within the University of Wisconsin System. The $418,872.19 contract is for research and development related to the Cancer Prevention Agent Development Program, which is focused on early phase clinical research. This contract is a delivery order under the Cancer...
- The National Cancer Institute issued a delivery order to the University of Wisconsin System on September 24, 2015, under the Cancer Prevention Agent Development Program 2012-2017 IDIQ for core infrastructure support related to early-phase clinical research in cancer prevention agent development, with a ceiling value of $4,057,707.83. Place of performance is Madison, Wisconsin. The order is cost-no-fee and has an ultimate completion date of September 23, 2019. No set-aside applies to this...
- The Department of Health and Human Services, National Institutes of Health, National Cancer Institute awarded a $709,235 Delivery Order contract to the University of Wisconsin System for core infrastructure support under the Cancer Prevention Agent Development Program 2012-2017 contract. This Cost-No-Fee contract does not have a set-aside designation and was awarded on September 23, 2014, with a completion date of September 23, 2015. The University of Wisconsin System, through its University...
- <p>The National Cancer Institute issued a delivery order to the University of Wisconsin System on September 20, 2013, with a ceiling value of $559,231, under the Cancer Prevention Agent Development Program 2012-2017 for a Phase IIA cancer chemoprevention biomarker study of intermittent erlotinib in subjects with bladder cancer.</p> <p>Place of performance is Madison, Wisconsin. The order is cost, no fee, and runs through September 30, 2018. No set-aside was used.</p>
- This is a federal contract award from the National Cancer Institute (NCI), a civilian agency within the U.S. government, to the University of Wisconsin System. The $1,214,305 contract is for a Phase I clinical trial to evaluate the safety and immunogenicity of a DNA plasmid-based vaccine (WOKVAC) that targets three breast cancer antigens (IGFBP-2, HER2, and IGF-IR). The contract is part of NCI's Cancer Prevention Agent Development Program, which focuses on early-stage clinical research. The...
- This is a definitive contract awarded by the National Cancer Institute (NCI), a civilian agency of the Department of Health and Human Services (HHS), to the University of Wisconsin Hospitals and Clinics Authority (UWHCA) on September 15, 1999. The contract, valued at $2,765,970.00, is for a randomized controlled Phase II clinical trial to study the modulation of intermediate endpoint biomarkers, as described in Workstatement No. 61. The contract does not have a set-aside designation and is...
- This is a $1,686,205.95 delivery order contract awarded by the National Cancer Institute (NCI) to the University of Texas MD Anderson Cancer Center (MD Anderson) to conduct a randomized pre-surgical clinical trial evaluating alternative dosing regimens of the cancer drug exemestane in postmenopausal women with early-stage estrogen receptor-positive breast cancer. The contract is part of NCI's Cancer Prevention Agent Development Program, which supports early phase clinical research on new...
- The National Cancer Institute issued a delivery order to the University of Wisconsin System on September 24, 2013, with a ceiling value of $572,545.00 under the Cancer Prevention Agent Development Program 2012-2017 for a Phase II exploratory, randomized, placebo-controlled trial of pomegranate fruit extract in subjects with clinically localized prostate cancer undergoing active surveillance. Place of performance is Madison, Wisconsin. The order ultimate completion date is September 23, 2019....
- This is a federal contract awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to the University of Oklahoma, a public research university, for the "Prevention of Endometrial Hyperplasia and its Transition to Endometrial Cancer with SHETA2" program. The $709,326.00 contract has a period of performance from June 1, 2017 to May 31, 2019, with a completion date of June 14, 2021. The contract falls under the "Preclinical...